NasdaqCM:CELCBiotechs
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts
Why Celcuity (CELC) is Drawing Fresh Attention
Celcuity (CELC) has come into focus after recent share price moves and its role as a clinical-stage biotechnology company working on targeted therapies for solid tumors, including advanced breast and prostate cancers.
See our latest analysis for Celcuity.
The current US$115.0 share price comes after a 6.2% 7 day share price return and an 11.9% 90 day share price return. The 1 year total shareholder return is very large, hinting that recent moves...